Leveraging Software to Lower Costs and Improve the Quality of Care

This panel focuses on investing in innovative digital health products that bring new efficiencies to the healthcare system, change how care is delivered or managed, and how patients are involved in their own care. Panelists will explore topics related to investing in digital health, including:

  • In what kinds of digital health technologies are they interested in investing?
  • What metrics and evidence do you look for in a digital health startup?
  • How can an early stage digital health company demonstrate the value of their products?
  • What are the main challenges for startups raising capital in this space?

The moderator and panelists will discuss this rapidly evolving field of healthcare investment, and will introduce the audience to the key fundraising opportunities and challenges facing digital health entrepreneurs today.


Request a Meeting

Ute Mercker, Investment Director of the Healthcare Team, IBB Ventures

Ute Mercker is Investment Director at the Life Sciences Team of IBB Beteiligungsgesellschaft, the regional Venture Capital funds of Berlin. Since 1997 she had been responsible for IBB´s Biotech and Medtech portfolio and managing investments into companies like Jerini or Scienion. Spin-offs from Universities or research institutions like Humedics, Scopis and EternyGen have always been an important part of her investment activities. Successful exits like the IPO / Takeover of Jerini AG (Charité Spin-off) by Shire as well as the latest trade sale of Scopis (TU Berlin / Charité Spin- off) to Stryker support this investment approach. Ute enjoys discussing and developing strategic and financial options with the founders / management / Board of their portolio companies. Ute represents the funds managed by IBB Beteiligungsgesellschaft as Board member of Humedics, Omeicos and Eternygen as well as the digital health startup Selfapy. She holds an MBA from the Freie Universität Berlin.

Request a Meeting

Terri Mead, Founder, Class Bravo Ventures

Terri Hanson Mead is the Managing Partner of Class Bravo Ventures and President of Solutions2Projects, LLC, a consulting company that provides IT strategy and IT compliance services in the life sciences space in addition to expert witness consulting services. She is an active angel investor, former Vice President of Sand Hill Angels, an EIR with Tech Futures Group, a Springboard advisor, a podcaster (Piloting Your Life), a speaker, a blogger, and regularly advises early stage startups across all sectors. Terri invests in early stage digital health startups, specifically FemTech and PediaTech. In her spare time, Terri flies helicopters. She is passionate about supporting, and advocating for, under-represented founders and investors. Terri’s startup investments have included MyHealthTeams, Sandstone Diagnostics, Zum, TomboyX, Tactical Haptics, Tueo Health, and Magnetic Insight. She participates in multiple funding rounds for select startups.

Request a Meeting

Sean Cheng, Senior Investment Manager, Philips Health Technology Ventures

Sean is currently an Investment Manager at Philips Ventures, a portfolio of promising health tech companies including Babyscripts, Xealth, Mytonomy, as well as a fund-of-funds to fulfill the Philips Healthtech strategy. He is interested in early-stage investment opportunities in digital health, medical devices and therapeutics. Previously, Sean held positions at the Boston Consulting Group, the U.S. FDA, and NASA. Sean also serves on the Board of Directors of The Professional Center for Child Development, Board of Advisors at the Johns Hopkins University, and the Advisory Council of the World Economic Forum’s Global Shapers Community. Sean holds a PhD in Engineering Design from the University of Cambridge in England, where he developed expertise in medical device design and optimization algorithms.

Request a Meeting

Richard Proscia, Senior Associate, Providence Ventures

Richard joined PV in 2019 as a Senior Associate. Prior to joining PV, he sat on the corporate innovation and development team at CVS Health, focused on digital health strategy, partnerships, and investments. Before CVS, Richard spent time on the corporate venture capital and development team at Athenahealth, where he focused on early stage investing, acquisitions, and partnerships for the More Disruption Please program. In his spare time, he also serves as an Advisor for TMCx, the Texas Medical Center Accelerator program and the MassChallenge HealthTech program. Richard is a graduate of Bentley University with a Bachelor’s of Science in finance and accounting.

Request a Meeting

Sven Dethlefs, EVP Global Marketing & Portfolio, Teva Pharmaceuticals Industries

Dr. Dethlefs became Executive Vice President, Global Marketing & Portfolio in November 2017. From 2016 to 2017, he served as Global Head of Respiratory Medicines, Global Specialty Medicines. From 2013 to 2016, he served as Chief Operating Officer, Teva Global Operations. Dr. Dethlefs joined Teva as General Manager, Teva Germany in 2008. Prior to joining Teva, he served for over eleven years as a partner at McKinsey & Company. Dr. Dethlefs received his Ph.D. in biochemistry from the FU Berlin/Pasteur Institute Paris.